Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 30 ... date, the company has submitted regulatory applications for Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, Adsorbed]), as it is known outside the U.S., in 60 ...
2009 SEP 7 ... performed. received one dose of either the PsA-TT conjugate vaccine, meningococcal A/C polysaccharide vaccine (PsA/C), or tetanus toxoid vaccine." "The conjugate vaccine was shown to ...
2009 SEP 28 ... meningitis and reduce child mortality." Highly effective and safe protein-polysaccharide conjugate Hib vaccines have been available for almost 20 years. These vaccines have ... vaccines exist to provide protection against both diseases. However, use of Hib vaccine has only recently expanded to low-income countries and pneumococcal vaccine is not yet ...
2009 NOV 29 ... to understand the influence of physician and practice characteristics on pneumococcal polysaccharide (PPV) and influenza vaccination rates. Analyzing data for 2,021 patients aged 65 and ... vaccination rates varied widely across individual physicians (11-98 percent for PPV vaccine and 22-96 percent for influenza vaccine). They also found that longer reported ...
2009 NOV 24 ... of morbidity and mortality in the elderly population. Although 23-valent pneumococcal polysaccharide vaccine (PPV) is recommended for elderly persons, the potential benefits of conjugate vaccine ...
2009 SEP 15 ... Research findings, 'Effects of a chemically derived homo zwitterionic polysaccharide on immune activation in mice,' are discussed in a new report. "In this study, a ... homoZPS could be a potential candidate in the development of T-lymphocyte dependent vaccine adjuvants." Meng and colleagues published their study in Acta Biochimica ...
2009 AUG 3 ... 7-valent pneumococcal conjugate vaccine (PCV7) followed by the 23-valent pneumococcal polysaccharide vaccine (PPV23) may offer better protection against invasive pneumococcal disease for older ...
2009 NOV 2 ... and protective efficacy of antibodies produced by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in chronic obstructive pulmonary disease (COPD). The 7-valent ...
2009 OCT 7 ... challenge with C. neoformans. In contrast, subcutaneous treatment with the capsular polysaccharide (PSC) emulsified in CFA exacerbates the cryptococcal infection." "The ... According to recent research published in the journal Clinical and Vaccine Immunology, "Previous studies in our laboratory have shown that the subcutaneous ...
2009 OCT 5 ... as determined by FITC-dextran exclusion. Next, we identified a link between polysaccharide structure and carriage prevalence. Significantly, non-vaccine serotypes that have become ...
2009 NOV 16 ... serving low-to middle-income white and minority patients relate to pneumococcal polysaccharide vaccine (PPV) and influenza vaccination rates. In an intentional sample of 18 primary care ...
2009 NOV 25 ... is administered to children at the age of 14 months. Here, we report the levels of MenC polysaccharide-specific antibodies in children at birth and at 3, 11, and 12 months of age and the ... Devoer and colleagues published their study in Clinical and Vaccine Immunology (Absence of Neisseria meningitidis Serogroup C-Specific Antibodies during the ...
2009 NOV 23 ... colleagues, University Hospital. The researchers concluded: "The 23-valent polysaccharide vaccine had a coverage of 91.1%." Imohl and colleagues published their study in ...
2009 AUG 31 ... "Anti-polysaccharide immunity is a key facet of protection against several bacterial pathogens. Problems ... mimics of type 6B and 9V pneumococcal capsular polysaccharides that could be used as vaccine antigens. Peptides mimicking antigenic properties of serotype 6B capsular polysaccharide ...
2009 NOV 2 ... There are three established approaches to anti-pneumococcal vaccination: capsular polysaccharide pneumococcal vaccine (PPV), protein-polysaccharide conjugate pneumococcal vaccine (CPV) ...
2009 AUG 3 ... based on state-of-the-art recombinant protein technology combined with our proprietary polysaccharide adjuvant system (Advax™)," he said. "This cutting-edge design means ... successfully undertaken the first ever human immunisations with a candidate swine flu vaccine. "This represents a major breakthrough as it is the first administration ...
2009 AUG 3 ... all the global burden of typhoid morbidity and mortality. One of these vaccines, Vi polysaccharide, is ideally suited to use in developing countries because it is cheap (about $.50 per ... A new study has found that a currently available yet underused vaccine against typhoid fever is highly effective in young children and protects unvaccinated ...
2009 OCT 12 ... opinion for the company's pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent Adsorbed]). The CHMP recommends approval of Prevenar 13 for ...
